Sellas Life Sciences has completed the 80th event in its Phase 3 REGAL trial of Galinpepimut-S for acute myeloid leukemia. The trial is designed to assess the drug's efficacy, with preliminary results expected this quarter. Analysts note that prolonged trial durations may increase the likelihood of failure. The company continues to monitor the trial's progress closely, with updates projected as the trial advances. The REGAL trial is a significant step in the development of Galinpepimut-S, which has shown encouraging results in previous phases. Sellas Life Sciences remains dedicated on advancing the drug through the regulatory process, with the goal of bringing a potential treatment to patients with acute myeloid leukemia. The company's careful approach to clinical trials and data analysis is strongly regarded in the industry, and investors are following the trial's outcome with attention.